



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: investorservices@suvenc.com website: www.suven.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FOR THE YEAR ENDED 31st MARCH, 2015

PART - I

Rs. in lakhs

Sl. No.	PARTICULARS	Quarter ended			Current year ended	Previous year ended
		31-Mar-2015	31-Dec-2014	31-Mar-2014	31-Mar-2015	31-Mar-2014
		Audited	Un-audited	Audited	Audited	Audited
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	11,066.25	12,882.97	13,080.34	52,085.50	51,031.24
	(b) Other operating income	-	-	-	-	-
	Total income from operations (net) (a)+(b)	11,066.25	12,882.97	13,080.34	52,085.50	51,031.24
2	Expenses					
	a) Cost of materials consumed	4,547.61	4,413.80	3,898.42	17,724.78	15,049.65
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(661.28)	(1,020.96)	339.57	347.95	(1,397.66)
	d) Employee benefits expense	995.18	963.42	710.62	3,651.16	3,144.21
	e) Depreciation and amortisation expense	244.71	244.73	227.51	976.38	883.74
	f) Other expenses - Manufacturing Expenses	1,639.72	1,812.03	1,600.29	6,444.21	5,388.94
	- R & D Expenses	1,359.31	1,279.47	1,238.05	4,632.39	4,794.79
	- Others	735.82	602.51	549.70	2,375.29	2,145.45
	Total expenses	8,861.07	8,295.00	8,564.16	36,152.16	30,009.12
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	2,205.18	4,587.97	4,516.18	15,933.34	21,022.12
4	Other Income	381.07	227.13	120.29	858.12	302.95
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	2,586.25	4,815.10	4,636.47	16,791.46	21,325.07
6	Finance costs	120.96	100.55	169.51	470.92	1,051.28
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	2,465.29	4,714.55	4,466.96	16,320.54	20,273.79
8	Exceptional Items (Ref: Note No.4 below)	200.44	236.58	-	1,165.07	-
9	Profit/Loss from Ordinary Activities before tax (7+8)	2,264.85	4,477.97	4,466.96	15,155.47	20,273.79
10	Tax Expenses	569.95	1,255.31	1,226.40	4,280.44	5,858.04
11	Net Profit/ (Loss) from Ordinary Activities after tax (9-10)	1,694.90	3,222.66	3,240.56	10,875.03	14,415.75
12	Extraordinary Items (net of tax expense Rs____)	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 + 12)	1,694.90	3,222.66	3,240.56	10,875.03	14,415.75
14	Share of profit / (loss) of associates	-	-	-	-	-
15	Minority interest	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	1,694.90	3,222.66	3,240.56	10,875.03	14,415.75
17	Paid-up equity share capital (Face Value of Rs. 1/- each)	1,272.82	1,272.82	1,168.29	1,272.82	1,168.29
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	54,658.58	25,276.34
19.i	Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	1.41	2.73	2.77	9.04	12.34
	b) Diluted	1.41	2.73	2.77	9.04	12.34
19.ii	Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	1.41	2.73	2.77	9.04	12.34
	b) Diluted	1.41	2.73	2.77	9.04	12.34

PART - II						
A	PARTICULARS OF SHAREHOLDING	31-Mar-2015	31-Dec-2014	31-Mar-2014	31-Mar-2015	31-Mar-2014
1	Public share holdings					
	a. Number of shares	51,624,902	51,624,902	41,171,212	51,624,902	41,171,212
	b. Percentage of share holding	40.56%	40.56%	35.24%	40.56%	35.24%
2	Promoters and promoter group Shareholding					
	a) Pledged / Encumbered					
	- Number of shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered					
	- Number of shares	75,657,576	75,657,576	75,657,576	75,657,576	75,657,576
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	59.44%	59.44%	64.76%	59.44%	64.76%
	Particulars	3 months ended (31/03/2015)				
B	INVESTOR COMPLAINTS					
	Pending at the beginning of the quarter	-				
	Received during the quarter	43				
	Disposed of during the quarter	43				
	Remaining unresolved at the end of the quarter	-				

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED						
	PARTICULARS	Quarter ended			Current year ended	Previous year ended
		31-Mar-2015	31-Dec-2014	31-Mar-2014	31-Mar-2015	31-Mar-2014
		Audited	Un-audited	Audited	Audited	Audited
1	SEGMENT REVENUE					
	a) Manufacturing (CRAMS)	10,785.75	12,328.69	12,683.73	50,016.03	49,344.00
	b) Services (DDSS)	280.50	554.28	396.78	2,069.47	1,687.24
	c) Research & Development	-	-	-	-	-
	Net sales/income from operations	11,066.25	12,882.97	13,080.51	52,085.50	51,031.24
2	SEGMENT RESULTS (Profit/(Loss) before tax and interest)					
	a) Manufacturing (CRAMS)	3,956.73	6,137.28	5,937.20	21,125.81	26,308.56
	b) Services (DDSS)	166.12	174.33	200.73	1,113.29	888.72
	c) Research & Development	(1,537.46)	(1,469.96)	(1,238.05)	(5,596.26)	(4,794.79)
	TOTAL	2,585.39	4,841.65	4,899.88	16,642.84	22,402.49
	Less: (i) Interest	61.28	65.34	89.44	286.05	618.92
	(ii) Other Un-allocable expenses net off	259.26	298.34	343.47	1,201.32	1,509.78
	(iii) un-allocable Income	-	-	-	-	-
	Profit Before Tax	2,264.85	4,477.97	4,466.97	15,155.47	20,273.79
3	CAPITAL EMPLOYED (Segment Assets-Segment Liabilities)					
	a) Manufacturing (CRAMS)	28,252.47	30,723.12	19,509.25	28,252.47	17,807.16
	b) Services (DDSS)	3,612.25	3,170.05	3,493.63	3,612.25	3,434.62
	c) Research & Development	558.65	841.37	1,815.26	558.65	1,460.97
	d) Un-allocated	32,151.43	29,106.35	1,626.50	32,151.43	10,453.81
	TOTAL	64,574.80	63,840.89	26,444.64	64,574.80	33,156.56

Notes:

- The above audited results were reviewed by Audit committee and approved by the Board of Directors' Meeting held on 26th May, 2015.
- Corresponding previous period figures have been regrouped/ reclassified whenever necessary.
- The Board has recommended a Dividend of Re. 0.60 per share (60% of face value Rs. 1.00 each), for the financial year 2014-15, The outflow on account of Dividend including dividend distribution tax is Rs. 919.17 lakhs.
- In accordance with Companies Act, 2013, the Company has revised the useful life of its fixed assets to comply with the life mentioned under Schedule II and as per the transitional provisions, the company has adjusted Rs. 469.06 lakhs (net of Def Tax charges of Rs. 248.25 lakhs) with the opening balances of retained earnings i.e. Surplus in the statement of profit & Loss. Had the Company continued to follow the earlier useful life, the depreciation would have been lower by Rs. 200.44 lakhs for this Qtr & Rs. 1165.07 lakhs for the full year as shown as exceptional item under item No 8 above. The Net Block of the fixed assets would have been higher by Rs. 1165.07 lakhs.
- The company has raised Rs. 200 Crores through QIP issue by allotment of 1,04,53,690 Equity shares of face value Re.1.00 each at a premium of Rs. 190.32 per share on 3rd December 2014.
- The Un-allocated assets as at 31st March, 2015 includes deposits with banks of Rs. 27,519.19 lakhs.
- The figures of the last quarter of the current year and previous year are the balancing figures between the audited figures in respect of the full financial year ended 31/03/2014 & 31/03/2015 and the unaudited published year to date figures for the 3rd quarters ended 31/12/2014 & 31/12/2013 respectively which were subjected to limited review.

For SUVEN LIFE SCIENCES LTD



VENKAT JASTI
Chairman & CEO
DIN: 00278028

Place : Hyderabad
Date: 26th May, 2015

We Deliver



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills,
Hyderabad - 500 034 CIN: L24110TG1989PLC009713

Standalone Statement of Assets & Liabilities as per Clause 41(V)(h) as per Listing Agreement

(Rs. In lakhs)

	Particulars	Year Ended	
		31-Mar-2015	31-Mar-2014
A	EQUITY AND LIABILITIES		
1	Shareholder's funds:		
	(a) Share Capital	1,272.82	1,168.29
	(b) Reserves and Surplus	54,658.58	25,276.34
	Sub-total - Shareholders' funds	55,931.40	26,444.63
2	Non-current liabilities		
	(a) Long-term borrowings	6,144.59	3,772.92
	(b) Long-term provisions	227.48	179.36
	(c) Deferred tax Liability (net)	2,271.34	2,759.66
	Sub-total - Non-current liabilities	8,643.41	6,711.94
3	Current liabilities		
	(a) Short-term borrowings	2,823.51	2,855.36
	(b) Trade payables	4,389.08	4,090.05
	(c) Other current liabilities	4,244.59	4,751.84
	(d) Short-term provisions	1,281.42	3,808.90
	Sub-total - Current liabilities	12,738.60	15,506.15
	TOTAL - EQUITY AND LIABILITIES	77,313.41	48,662.72
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	27,896.26	19,205.41
	(b) Non-current investments	-	0.15
	(c) Deferred tax assets (net)	-	-
	(d) Long-term loans and advances	1,088.74	1,263.72
	(e) Other Non-current assets	630.54	141.73
	Sub-total - Non-current assets	29,615.54	20,611.01
2	Current assets		
	(a) Current investments	3.64	3.64
	(b) Inventories	8,180.55	7,862.87
	(c) Trade receivables	4,016.91	6,547.03
	(d) Cash and cash equivalents	27,968.90	6,798.22
	(e) Short-term loans and advances	7,459.79	6,804.20
	(f) Other current assets	68.08	35.75
	Sub-total - Current assets	47,697.87	28,051.71
	TOTAL - ASSETS	77,313.41	48,662.72

For Suven Life Sciences Ltd

Venkat Jasti
Chairman & CEO
DIN: 00278028



Auditor's Report on Quarterly Financial Results and Year to Date Financial Results of Suven Life Sciences Limited pursuant to Clause 41 of the Listing Agreement

To
The Board of Directors of **Suven Life Sciences Limited**

We have audited the quarterly financial results of **Suven Life Sciences Limited** ('the Company') for the quarter ended 31st March, 2015 and the year to date financial results for the period from 1st April, 2014 to 31st March, 2015, attached herewith, being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding', which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principle generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us, these quarterly financial results as well as the year to date financial results:


- (i) are presented in accordance with the requirements of Clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the **NET PROFIT** and other financial information for the quarter ended 31st March, 2015 as well year to date results for the period from 1st April, 2014 to 31st March, 2015.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the Company in terms of Clause 35 of the Listing Agreement and found the same to be correct.

For **KARVY & CO.**
Chartered Accountants
Firm Registration No: 001757S


(**K. AJAY KUMAR**)
Partner
Membership No. 021989

Place: Hyderabad
Date : 26/05/2015





News Release

Suven's Income increased by 3% and PAT lower by 25% for the year ended March 2015

HYDERABAD, INDIA (26th May, 2015) – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, and Contract Research and Manufacturing Services (CRAMS) today announced its audited financial results for the year ended 31st Mar 2015. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 26th May 2015 at Hyderabad.

Financial Highlights for the year ended Mar' 2015:

Growth in revenue	Rs. 5294 Mn vs. Rs 5133 Mn	- Up by 3%
Growth in PAT	Rs. 1088 Mn vs. Rs 1442 Mn	- Down by 25%
Growth in EBIDTA	Rs. 1680 Mn vs. Rs 2221 Mn	- Down by 24%

Financial Highlights for the 4th Quarter ended Mar' 2015:

Growth in revenue	Rs 1145 Mn vs. Rs 1320 Mn	- Down by 13%
Growth in PAT	Rs 169 Mn vs. Rs 324 Mn	- Down by 48%
Growth in EBIDTA	Rs 265 Mn vs. Rs 486 Mn	- Down by 45%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 560 Mn (10.57% on revenue) for the year ended March 31, 2015

The Board has proposed a Dividend of Re. 0.60 per share (60% of face value Rs. 1.00 each) for the financial year 2014-15, subject to approval of the shareholders in the ensuing Annual General Meeting.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com